Abstract
Herein, the development of ruthenium complexes as potential apoptosis inducers, as well as their underlying mechanism has been reviewed. In recent years, various ruthenium complexes have been designed and their in vitro and in vivo inhibitory activities against various types of tumor cells have been evaluated extensively. It’s demonstrated that ruthenium complexes can induce apoptosis of tumor cells through the signal pathway of mitochondria-mediated, death receptor-mediated, and/or endoplasmic reticulum (ER) stress pathways. Alternately, the binding behavior of these ruthenium(II) complexes with DNA, especially with Gquadruplex DNA may play a key role in the DNA damage of tumor cells, and thus provides a versatile tool to rational design novel ruthenium complexes with high activity and selectivity.
Keywords: Ruthenium complexes, apoptosis, mitochondria, G-quadruplex, endoplasmic reticulum.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Ruthenium(II) Complexes as Potential Apoptosis Inducers in Chemotherapy
Volume: 17 Issue: 1
Author(s): Kangdi Zheng, Qiong Wu, Chengxi Wang, Weijun Tan and Wenjie Mei
Affiliation:
Keywords: Ruthenium complexes, apoptosis, mitochondria, G-quadruplex, endoplasmic reticulum.
Abstract: Herein, the development of ruthenium complexes as potential apoptosis inducers, as well as their underlying mechanism has been reviewed. In recent years, various ruthenium complexes have been designed and their in vitro and in vivo inhibitory activities against various types of tumor cells have been evaluated extensively. It’s demonstrated that ruthenium complexes can induce apoptosis of tumor cells through the signal pathway of mitochondria-mediated, death receptor-mediated, and/or endoplasmic reticulum (ER) stress pathways. Alternately, the binding behavior of these ruthenium(II) complexes with DNA, especially with Gquadruplex DNA may play a key role in the DNA damage of tumor cells, and thus provides a versatile tool to rational design novel ruthenium complexes with high activity and selectivity.
Export Options
About this article
Cite this article as:
Zheng Kangdi, Wu Qiong, Wang Chengxi, Tan Weijun and Mei Wenjie, Ruthenium(II) Complexes as Potential Apoptosis Inducers in Chemotherapy, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (1) . https://dx.doi.org/10.2174/1871520616666160622085441
DOI https://dx.doi.org/10.2174/1871520616666160622085441 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Perspectives for Novel Mixed Diruthenium-Organic Drugs as Metallopharmaceuticals in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry N-Succinyl Chitosan as Buccal Penetration Enhancer for Delivery of Herbal Agents in Treatment of Oral Mucositis
Current Drug Delivery Merging Transport Data for Choroid Plexus with Blood-Brain Barrier to Model CNS Homeostasis and Disease More Effectively
CNS & Neurological Disorders - Drug Targets Methodological Aspects and Applications of In Vivo Imaging of Apoptosis in Oncology: An Illustrative Review
Current Medical Imaging Molecular Mechanisms and Proposed Targets for Selected Anticancer Gold Compounds
Current Topics in Medicinal Chemistry Combined Chemotherapy or Biotherapy with Jasmonates: Targeting Energy Metabolism for Cancer Treatment
Current Pharmaceutical Biotechnology Atypical Manifestations of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children: A Systematic Review
Current Pediatric Reviews [11C]Meta-Hydroxyephedrine PET/CT
Current Radiopharmaceuticals Recent Developments in the Applications of Palladium Complexes Bearing N-Heterocyclic Carbene Ligands
Current Organic Chemistry Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets Recent Patent-Based Perspective on Diagnostic and Therapeutic Interventions in Malignant Mesothelioma: Is Drug Repositioning Knocking on the Door?
Recent Patents on Anti-Cancer Drug Discovery Back to the Future: COX-2 Inhibitors for Chemoprevention and Cancer Therapy
Mini-Reviews in Medicinal Chemistry Platinum Compounds: A Hope for Future Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry A Facile and Microwave-assisted Rapid Synthesis of 2-Arylamino-4-(3′-indolyl)- thiazoles as Apoptosis Inducing Cytotoxic Agents
Anti-Cancer Agents in Medicinal Chemistry Role of C1QBP/p32 and its Therapeutic Potential in Breast Carcinoma and other Cancers
Current Medicinal Chemistry Signal Transduction and Heavy Ion Radiation Therapy: Biological Mechanisms, Biological Quality Assurance, and New Multimodality Approach
Current Signal Transduction Therapy Design, Synthesis and Evaluation of Hybrid 2-Heteroaryl Benzimidazole- Chalcone Derivatives as Anticancer Agents
Letters in Organic Chemistry Targeting Tumors with Small Molecule Peptides
Current Cancer Drug Targets Murine Models of Vpr-Mediated Pathogenesis
Current HIV Research The Prognostic Value of Long Non-Coding RNA <i>SNHG7</i> in Human Cancer: A Meta-Analysis
Current Pharmaceutical Biotechnology